| abstract |
The present invention provides methods of detecting cancer using biomarkers . In particular, a reduced amount of a peptide marker derived from the C-domain of the fibrinogen alpha, e.g. fragment 605-629 of fibrinogen alpha precursor, in a patient sample, e.g. serum, is indicative of the presence or the progression of a proliferative disorder, e.g. breast cancer. Contrary to these fibrogen markers, haemoglobin polypeptides are indicative of a cancer if their amount is higher in patient samples than in controls. |